Low-Risk Simplified Dossier in Saudi Arabia: Six Documents and the 10-Day Rule

1. Key takeaways

Low-risk devices in Saudi Arabia may submit only 6 items: device description and specification, information supplied by the manufacturer, the Essential Principles Checklist, evidence of conformity, the risk management file, and post-market surveillance plans and reports. This benefit excludes five situations: IVDs, sterile devices, devices with a measuring function, reusable surgical instruments, and innovative products. The price is the 10-day clause in the same Notes: the SFDA may request the full technical documentation at any time, and it must be submitted within 10 days of the request. The GRZAN conclusion is that what is simplified is the submission list, not the obligation to build the dossier.

• The 6-item list applies only to low-risk devices outside the five excluded categories.
• The five exclusions mirror the eligibility conditions of the MDNR light pathway almost exactly.
• The 10-day clause gives the reviewer, not the applicant, the choice of whether the full dossier must be produced.
• The simplified list and the reliance pathway are independent: one governs how many items are submitted, the other which review channel applies.
• Item 6 of the list, the post-market surveillance plan, links the application directly to the reporting duties under MDS-REQ 11.
• Vigilance reporting under MDS-REQ 11 runs on three timeframes of 2, 10, and 30 days.

2. Legal basis

The table below lists the instruments relied upon, their document numbers and dates, the relevant clauses, and the key points of the original text. Regulatory information verified as of October 29, 2026.

3. Expert insights

The six-item list and the MDNR exclusions share one logic, which reveals the conservative orientation of the SFDA. The five excluded situations under the 6-item simplified list overlap almost completely with the eligibility conditions of the MDNR light pathway: Class A, not an IVD, not sterile, no measuring function, not a reusable surgical instrument, not innovative. This is not coincidence but the projection of a single risk philosophy onto two rules. The SFDA opens up the document requirements only for products whose failure consequences remain controllable.

This shared logic yields a practical inference: if a product is excluded from the simplified list because it is sterile or has a measuring function, it most likely cannot take the MDNR either and must return to the full MDMA. Manufacturers can therefore run one quick qualitative screen using this set of exclusion conditions during pathway selection, instead of discovering a pathway mismatch only at submission. The logic for choosing between MDMA and MDNR is set out at https://www.grzan.cn/regulations/saudi/mdma-versus-mdnr-listing-11 .

The 10-day clause hands the choice of whether to submit to the reviewer. The significance of the 10-day clause lies not in the length of the deadline but in who holds the trigger. An applicant cannot permanently discharge the obligation to hold the full technical documentation by submitting only 6 items; the obligation can only be deferred until the SFDA asks. Because retrieval notices arrive unpredictably, the company effectively carries an open-ended commitment.

For Chinese manufacturers, physical cross-border retrieval time is the dominant risk. The complete technical documentation normally sits with the manufacturer and involves foreign stamping, scanning, translation, and transfer. Even in the best case, 10 days is close to the limit. The GRZAN practice is to replicate the complete documentation at the in-country responsible entity at the time of submission and keep the versions synchronized.

The simplified list and the reliance pathway are not mutually exclusive: the former governs how many items are submitted, the latter which review channel is used. A product satisfying both sets of conditions can submit 6 items while still entering the 35 to 60 working day review channel. However, the eligibility tests are independent: passing the reliance pathway does not reduce the documents further, and submitting the simplified list does not automatically confer reliance eligibility (a practical estimate, subject to the actual field behavior in the GHAD portal).

Hidden workload beyond the six items: the post-market surveillance plan. Item 6 of the 6-item list is the post-market surveillance plans and reports. It is often mistaken for a formality, yet it wires the application directly into post-market obligations: once certification is obtained, the adverse event reporting timeframes under MDS-REQ 11, namely 2 days, 10 days, and 30 days, take effect immediately, with reporting channels comprising the NCMDR, Saudi Vigilance, and the call center 19999.

The plan must therefore name the responsible persons, the reporting route, and the rules for determining which timeframe applies, rather than stating simply that reports will follow SFDA requirements. When GRZAN drafts this item it is written as an executable internal procedure: who receives the signals, who decides the tier, and who submits to the NCMDR within the deadline are set out separately. The full breakdown of post-market obligations appears at https://www.grzan.cn/regulations/saudi/post-market-surveillance-ncmdr-and-saudi-vigilance-41 .

4. Practical recommendations

• Run the exclusion screen first: if the product falls into any of the categories of IVD, sterile, measuring function, reusable surgical instrument, or innovative product, the 6-item list does not apply.
• Even if the simplified list applies, build the complete technical documentation before submission and keep an immediately retrievable copy with the in-country authorised representative (AR) or the responsible project party.
• Record the retrieval contact and time zone on the cover and version history pages of the complete documentation to compress cross-border communication cost.
• Complete the EP Checklist row by row, with one evidence anchor per row, and leave no blanks or notes referring the reviewer to other documents.
• Write the risk management file to the structure of ISO 14971 and cross-reference it with the risk control rows of the EP Checklist; see https://www.grzan.cn/regulations/saudi/risk-management-file-iso-14971-25 .
• The post-market surveillance plan must name the NCMDR liaison, the rules for determining reporting timeframes, and the three reporting channels, and must designate a responsible contact inside Saudi Arabia.
• Open a change ledger immediately after certification and test any change of model, material, or label against the significant change criteria first; see https://www.grzan.cn/regulations/saudi/significant-and-non-significant-change-46 .
• If the fee difference between MDNR and MDMA is being assessed at the same time, factor in https://www.grzan.cn/regulations/saudi/sfda-mdma-fee-structure-sar-38 .

5. Verification checklist

• □ Confirmed item by item that the product is not an IVD, sterile, a measuring-function device, a reusable surgical instrument, or an innovative product
• □ The risk class has been confirmed and supporting e-GHAD or SFDA classification evidence retained
• □ The 6 items are complete: description and specification, manufacturer information, EP Checklist, evidence of conformity, risk management file, and PMS plans and reports
• □ The EP Checklist has no empty rows and every row has an evidence anchor
• □ The complete technical documentation is ready and can be produced in-country within 10 days
• □ A retrieval contact has been designated, with time zone and contact details recorded
• □ The post-market surveillance plan states the NCMDR reporting route and the rules for determining the three timeframes
• □ The AR is in place with valid authorization (a mandatory item for foreign manufacturers)

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Saudi Arabian market. Our team prepares SFDA-compliant STAR dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com